Simone Picelli

Dr. Simone Picelli

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2023 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
PWPhilipp Wahle
Philipp Wahle
GBGiovanna Brancati
Giovanna Brancati
CHChristoph Harmel
Christoph Harmel
ZHZhisong He
Zhisong He
GGGabriele Gut
Gabriele Gut
JCJ. Gray Camp
J. Gray Camp
Organoids generated from human pluripotent stem cells provide experimental systems to study development and disease, but quantitative measurements across different spatial scales and molecular modalities are lacking. In this study, we generated multiplexed protein maps over a retinal organoid time course and primary adult human retinal tissue. We developed a toolkit to visualize progenitor and neuron location, the spatial arrangements of extracellular and subcellular components and global patterning in each organoid and primary tissue. In addition, we generated a single-cell transcriptome and chromatin accessibility timecourse dataset and inferred a gene regulatory network underlying organoid development. We integrated genomic data with spatially segmented nuclei into a multimodal atlas to explore organoid patterning and retinal ganglion cell (RGC) spatial neighborhoods, highlighting pathways involved in RGC cell death and showing that mosaic genetic perturbations in retinal organoids provide insight into cell fate regulation.

30 May 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
VHVincent Hahaut
Vincent Hahaut
DPDinko Pavlinic
Dinko Pavlinic
WCWalter Carbone
Walter Carbone
SSSven Schuierer
Sven Schuierer
PBPierre Balmer
Pierre Balmer
SPSimone Picelli
Simone Picelli
We present FLASH-seq (FS), a full-length single-cell RNA sequencing (scRNA-seq) method with increased sensitivity and reduced hands-on time compared to Smart-seq3. The entire FS protocol can be performed in ~4.5 hours, is simple to automate and can be easily miniaturized to decrease resource consumption. The FS protocol can also use unique molecular identifiers (UMIs) for molecule counting while displaying reduced strand-invasion artifacts. FS will be especially useful for characterizing gene expression at high resolution across multiple samples.


8 January 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AMAlissa Muller
Alissa Muller
JSJack Sullivan
Jack Sullivan
WSWibke Schwarzer
Wibke Schwarzer
MWMantian Wang
Mantian Wang
CPCindy Park-Windhol
Cindy Park-Windhol
BGBence György
Bence György
Stargardt disease is a currently untreatable, inherited neurodegenerative disease that leads to macular degeneration and blindness due to loss-of-function mutations in the ABCA4 gene. We have designed a dual adeno-associated viral vector encoding a split-intein adenine base editor to correct the most common mutation in ABCA4 (c.5882G>A, p.Gly1961Glu). We optimized ABCA4 base editing in human models, including retinal organoids, induced pluripotent stem cell-derived retinal pigment epithelial (RPE) cells, as well as adult human retinal explants and RPE/choroid explants in vitro. The resulting gene therapy vectors achieved high levels of gene correction in mutation-carrying mice and in female nonhuman primates, with average editing of 75% of cones and 87% of RPE cells in vivo, which has the potential to translate to a clinical benefit. No off-target editing was detectable in human retinal explants and RPE/choroid explants. The high editing rates in primates show promise for efficient gene editing in other ocular diseases that are targetable by base editing.

15 April 2026 in Nature
Verified
Journal Article
Open access
PDF file
TATemurkhan Ayupov
Temurkhan Ayupov
VMVerónica Moreno-Juan
Verónica Moreno-Juan
SCSerena Curtoni
Serena Curtoni
AFAlex Fratzl
Alex Fratzl
USUpnishad Sharma
Upnishad Sharma
BRBotond Roska
Botond Roska
A number of currently untreatable diseases, including neurodegenerative disorders, optic nerve atrophy and heart failure, are associated with mitochondrial dysfunction. Transplantation of healthy mitochondria has been proposed as a potential therapeutic strategy1,2,3. However, the lack of methods to target donor mitochondria to disease-affected cell types limits treatment specificity and efficacy. Here we developed MitoCatch as a system to deliver mitochondria to specific cell types using different types of protein binders. Donor mitochondria are captured by target cells by cell-surface-displayed monospecific binders, mitochondrion-displayed monospecific binders or bispecific binders linking mitochondria to target cells. Using MitoCatch, we show that donor mitochondria are efficiently internalized, exposed to the cytosol, move, and undergo fusion and fission inside target cells. By engineering binders with different affinities, we tune the efficiency of mitochondrial delivery. We demonstrate targeted mitochondrial transplantation to retinal cell types, neurons and cardiac, endothelial and immune cells in humans and mice. Transplanted mitochondria promoted the survival of damaged neurons from an individual with optic nerve atrophy in vitro and after neuronal injury in mice in vivo. MitoCatch is a potential strategy to target disease-affected cell types with mitochondria in organs affected by diseases associated with mitochondrial dysfunction.

11 December 2022
Verified
Book Chapter
Closed access
PDF file
VHVincent Hahaut
Vincent Hahaut
SPSimone Picelli
Simone Picelli